AFMD
HEALTHCAREAffimed N.V.
—PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving AFMD Today?
No stock-specific AI insight has been generated for AFMD yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-5.09
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding16.4M
AFMD News
5 articles- Phreesia (PHR) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 28, 2025
- Biotech Alert: Searches spiking for these stocks todayYahoo Finance·May 20, 2025
- Bluebird extends deal deadline; Affimed files for insolvencyBiopharmadive·May 14, 2025
- Affimed Announces Receipt of Nasdaq Delisting NoticeYahoo Finance·May 14, 2025
- Affimed Announces Filing for the Opening of Insolvency ProceedingsYahoo Finance·May 13, 2025
All 5 articles loaded
Price Data
Open—
Previous Close—
Day High—
Day Low—
52 Week High$0.73
52 Week Low$0.07
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-5.09
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding16.4M
About Affimed N.V.
Affimed NV, a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. The company is headquartered in Heidelberg, Germany.
Listed September 12, 2014
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—